MedTrace Logo

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-09-25

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).

Conditions

  • Frontotemporal Dementia

Interventions

DRUG

Flortaucipir F18

370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose

PROCEDURE

Brain PET scan

positron emission tomography (PET) scan of the brain

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Avid Radiopharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-11
Primary Completion
2018-10-24
Completion
2018-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03040713 on ClinicalTrials.gov